1671 / 2063
ESTRO
2017
Pelvic radiation with concurrent chemotherapy compared
with pelvic and para-aortic radiation for high-risk cervical
cancer.
M. Morris et al, NEJM, 340:1137-1143, 1999.
RT RT+Chemo
(n=193) (n=195)
5y overall survival
58%
73 (p=0.004)
LR recurrence
35%
19% (p<0.001)
Distant relapse
33%
14% (p<0.001)
RT: 45 Gy + brachytherapy (total dose ≥ 85 Gy)
Chemo: cddp (75mg/m
2
, d1), 5Fu (1g/m
2
/d, d1-4), x3
ESTRO
2017
Combined chemo- and radiotherapy
treatment
• Spatial co-operation (e.g. breast carcinoma)
• Independent cell kill (e.g. Hodgkin lymphoma)
• Interaction (e.g. H&N, cervix, NSCLC)
• “diluted” toxicity (e.g. Hodgkin lymphoma)